Bladder cancer is the most common urinary tract malignancy in the United States, with an estimated 84,530 new cases and 18,870 deaths projected in 2026. It is predominant in older adults: 90% of cases occur in patients 55 and older, with a median diagnosis age of 73. Early recognition is essesntial. Five-year survival reaches approximately 96% for non-muscle-invasive disease, but drops to roughly 5% once metastatic. Among all solid tumors, bladder cancer carries one of the highest recurrence rates, 50 to 70% of non-muscle-invasive cases recur, and up to 25% progress to muscle-invasive disease within five years.
AAVBC's Bladder Cancer Quick Reference Guide equips primary care clinicians and care teams with a practical, evidence-aligned reference covering hematuria recognition, disease staging, surveillance protocols, ICD-10 subsite coding, MEAT documentation standards, and common coding pitfalls. Grounded in current AUA and NCCN guideline evidence, this guide helps care teams recognize bladder cancer earlier, document clinical complexity accurately, and keep surveillance coordinated with the continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of bladder cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Bladder cancer is the most common urinary tract malignancy in the United States, with an estimated 84,530 new cases and 18,870 deaths projected in 2026. It is predominant in older adults: 90% of cases occur in patients 55 and older, with a median diagnosis age of 73. Early recognition is essesntial. Five-year survival reaches approximately 96% for non-muscle-invasive disease, but drops to roughly 5% once metastatic. Among all solid tumors, bladder cancer carries one of the highest recurrence rates, 50 to 70% of non-muscle-invasive cases recur, and up to 25% progress to muscle-invasive disease within five years.
AAVBC's Bladder Cancer Quick Reference Guide equips primary care clinicians and care teams with a practical, evidence-aligned reference covering hematuria recognition, disease staging, surveillance protocols, ICD-10 subsite coding, MEAT documentation standards, and common coding pitfalls. Grounded in current AUA and NCCN guideline evidence, this guide helps care teams recognize bladder cancer earlier, document clinical complexity accurately, and keep surveillance coordinated with the continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of bladder cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
